Latest Equities News

Cynata Therapeutics has successfully raised $1.2 million through an At-The-Market equity raise, issuing shares at a discount to support its ongoing clinical programs. This capital injection aims to bolster working capital as the company advances its proprietary stem cell therapies.

CD Private Equity Fund II announces a $0.38 per unit distribution reflecting recent portfolio realisations, delivering nearly double the initial investment in returns since inception.

CD Private Equity Fund I announces a $0.05 per unit distribution, bringing total returns close to twice the initial investment since inception.

Insignia Financial has responded to ASX concerns over past disclosures of performance rights, affirming shareholder approvals and outlining improved compliance measures.

Multistack International Limited reported a net operating cash outflow of A$196,577 for the December quarter but maintains a solid cash buffer as it pursues the sale of its Australian subsidiary.

Cyprium Metals has raised A$41 million through an oversubscribed equity placement and entitlement offer to accelerate exploration and production growth at its flagship Nifty Copper Complex and regional projects.

West Wits Mining has transitioned its Qala Shallows project from mobilisation to underground production, delivering first ore to surface and targeting its first gold pour in March 2026. The company has secured substantial funding to support this milestone and future growth.

Visionflex Group Limited reported a mixed quarter with a modest cash burn but strengthened its balance sheet through a significant debt-to-equity conversion and maintained solid funding capacity.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Euroz Hartleys reports a striking 121% jump in net profit for H1 FY2026, driven by booming equity capital markets activity and rising advisory fees. The company also lifts its interim dividend, signalling confidence amid cyclical market conditions.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

American Tungsten & Antimony Ltd is progressing its Nasdaq listing plans with a confidential SEC filing expected in March 2026 and has appointed Deutsche Bank as ADR depositary alongside a new CFO to support growth.